var path='http://www.tickertech.com'; function heading(heading) { document.write('

'+ ''+ '
• '+heading+'
'+ ''+ '

'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("selfdirectedinvestor.com") > 0) || (ref.indexOf("128.241.244.123") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("marketnewsvideo.mobi") > 0) || (ref.indexOf("206.71.145.70") > 0) || (ref.indexOf("206.71.145.73") > 0) || (ref.indexOf("206.71.145.76") > 0) || (ref.indexOf("selfdirectedinvestor.mobi") > 0) || (ref.indexOf("google.") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
•\; Basic Quotes - MRK Sunday, April 28, 3:21 PM\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
Please click on a symbol to receive a detailed quote. At least 20 min. delay. \;
\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
Symbol Last Trade Change Volume More Info
MRK 4:00 p.m. 131.20
\;0.48
\;0.37%
7,758,230 \n'); } if (allow) { document.write('detailed quote \n'); } if (allow) { document.write('chart
news profile \n'); } if (allow) { document.write(' ValueForum rating \n'); } if (allow) { document.write(' \n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
Enter symbols: \;
\n'); } if (allow) { document.write(' \;symbol lookup \; \; Find more stocks like \;
\n'); } if (allow) { document.write('

\n'); } heading('Related News'); if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('

4/25 - 10:57 AM \; \;	Dow Movers: IBM, MRK [VIDEO]
4/25 - 6:30 AM \; \;	Merck Announces First-Quarter 2024 Financial Results
4/19 - 7:06 AM \; \;	Health Canada Approves KEYTRUDA®\; as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
4/19 - 7:05 AM \; \;	Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
4/4 - 6:45 AM \; \;	Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
4/3 - 8:00 AM \; \;	REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
4/1 - 6:45 AM \; \;	Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
3/28 - 9:16 AM \; \;	How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
3/28 - 6:45 AM \; \;	European Commission Approves Merck\'s KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
3/27 - 10:20 AM \; \;	S&P 500 Movers: CCL, CTAS [VIDEO]
3/27 - 10:19 AM \; \;	Dow Movers: V, MRK [VIDEO]
3/26 - 6:21 PM \; \;	FDA Approves Merck\'s WINREVAIR™\; (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO Group 1)
3/26 - 9:31 AM \; \;	Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
3/21 - 6:45 AM \; \;	Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Maintenance LYNPARZA (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
3/20 - 10:13 AM \; \;	Dow Movers: CAT, CSCO [VIDEO]

more news	\n'); } if (allow) { document.write(' \n'); } if (allow) { document.write('Enter search terms: \;\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('

Access Denied

'+ '

Please Read This Important Message

'+ ' If you are a paying TickerTech.com client and your account was not set up to include the configuration'+ ' received, please email support@tickertech.com,'+ ' or call us at 1-866-515-2082 to verify your account settings.'+ ' '+ '

'+ ' '+ '

If you reached this page'+ ' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+ ' paying client. For pricing information please visit our products page, email '+ ' services@tickertech.com, or give us a call at 1-866-515-2082.'+ ' '+ '

'+ ' '+ ' TickerTech.com home
'+ ' TickerTech.com products'+ '
'+ ' '+ ''); } }

•\; Basic Quotes - MRK	Sunday, April 28, 3:21 PM\n'); } if (allow) { document.write('